Trial intelligence / Profile preview

Neoadjuvant chemotherapy versus surgery alone in high-risk resectable colorectal liver metastases

2013-004952-39Phase 3Terminated

Sponsor
Erasmus MC Cancer Institute
Start
Jul 2014
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised trial of oxaliplatin and capecitabine in colorectal cancer liver metastasis (CRLM) (2 arms), sponsored by Erasmus MC Cancer Institute. Primary endpoint: overall survival. Started Jul 2014; status: terminated.

02

Drugs

oxaliplatincapecitabine
03

Conditions

colorectal cancer liver metastasis (CRLM)

Beyond the preview

Go deeper on 2013-004952-39.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-004952-39.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call